Fei Re Qing Granules

PreclinicalSmall molecule

HHenan University of Traditional Chinese Medicine

Fei Re Qing Granules is one of 36 small molecule programs targeting Pneumonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Gram-Negative Bacterial InfectionsActive, not recruiting

Severe PneumoniaRecruiting

PneumoniaPreclinical

Active, not recruiting

Gram-Negative Bacterial InfectionsPreclinical

Active, not recruiting

Severe PneumoniaPreclinical

Recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Prevacid

Takeda

Preclinical

1 2

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 3

Zantac 150

CChattem

Preclinical

2 4

Pepcid

KKenvue Brands

Preclinical

1 5

Mucinex

AAultman Health Foundation

Preclinical

1 6

Tagamet

DDT MedTech, LLC

Preclinical

1 7

Piperacillin/tazobactam

Pfizer

Preclinical

2 8

PCV13

Sanofi

Preclinical

1 9

Hydroxychloroquine Sulfate

Novartis

Preclinical

1 10

Angiotensin Receptor Blockers

TThe George Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Severe Pneumonia

NCT07206745

Clinical

Trials by Indication[1]

Pneumonia1 trial

Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia

Not yet recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06747325·120 enrolled

Severe Pneumonia1 trial

Efficacy Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

Recruiting·HHenan University of Traditional Chinese Medicine·Preclinical·NCT07206745·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fei Re Qing Granules. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fei Re Qing Granules compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fei Re Qing Granules. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenan University of Traditional Chinese Medicine

Fei Re Qing Granules

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pneumonia1 trial

Severe Pneumonia1 trial

References

Drug Info

Quick Facts

Related News